Matsuura G K, Chan L A
Pacific Presbyterian Medical Center, San Francisco, CA.
Drug Intell Clin Pharm. 1988 Nov;22(11):883-5. doi: 10.1177/106002808802201110.
The drug of choice in the treatment of chloroquine-resistant Plasmodium falciparum malaria is parenteral quinine dihydrochloride. Due to limited use, the drug is not commercially available in the U.S. and must be obtained through the Centers for Disease Control (CDC) in Atlanta, Georgia. As an alternative, the CDC has developed a protocol to treat P. falciparum malaria with parenteral quinidine gluconate. Following this protocol, a 10 mg/kg loading dose of quinidine gluconate followed by a 0.02 mg/kg/min continuous infusion was administered to a 53-year-old man with severe life-threatening chloroquine-resistant P. falciparum malaria. Although the patient described did not survive, the use of parenteral quinidine gluconate still appears to be a viable alternative to parenteral quinine dihydrochloride in the treatment of severe chloroquine-resistant P. falciparum malaria.
治疗耐氯喹恶性疟原虫疟疾的首选药物是胃肠外注射二盐酸奎宁。由于使用受限，该药物在美国没有商业供应，必须通过位于佐治亚州亚特兰大的疾病控制中心（CDC）获取。作为替代方案，CDC制定了一项用胃肠外注射葡萄糖酸奎尼丁治疗恶性疟原虫疟疾的方案。按照该方案，一名患有严重危及生命的耐氯喹恶性疟原虫疟疾的53岁男子接受了10mg/kg的葡萄糖酸奎尼丁负荷剂量，随后以0.02mg/kg/分钟的速度持续输注。尽管所述患者未能存活，但在治疗严重耐氯喹恶性疟原虫疟疾方面，胃肠外注射葡萄糖酸奎尼丁似乎仍是胃肠外注射二盐酸奎宁的可行替代方案。
